about us

Bold vision.

Our vision is to take a major step forward in vaccine innovation to prevent and combat a wide range of infectious and other immune-mediated diseases, protecting infants and adults in our communities and making a meaningful impact on global public health.

A company pioneering a novel class of vaccines.

Affinivax is a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines, using its patented biotin-rhizavidin binding approach to optimize the body’s protective immune response to address infectious and other immune-mediated diseases. Our novel and highly efficient vaccine technology – called Multiple Antigen Presenting System (MAPS™) – enables the precise, high affinity binding of protective polysaccharide to protein antigens in a single vaccine, uniquely inducing a broad and protective B-cell (antibody) and T-cell immune response. We tailor the design of each of our vaccine candidates to optimize the protective immune response to one or both of these types of antigens utilizing the distinctive plug-and-play capability of MAPS technology.

Affinivax is focused on developing vaccines for the most challenging bacterial infections, with a goal of improving upon existing vaccines and providing solutions for where there are no vaccines or prevention strategies available today. Our lead vaccine, developed in partnership with Astellas Pharma, targets Streptococcus pneumoniae and has completed a Phase 2 clinical trial in adults. Including 24 pneumococcal serotypes and 2 highly conserved pneumococcal proteins, this vaccine offers the potential to induce broader protection than any pneumococcal vaccine on the market or in clinical testing today. In addition, we are advancing a pipeline of MAPS vaccines targeting the most common healthcare-associated infections that impact millions of adults across all medical facilities. We are also extending the utility of MAPS to a range of other potential applications, including vaccines and immunotherapies for viral infections and cancer.

Affinivax has an exclusive license for the MAPS technology platform from Boston Children’s Hospital..

Learn More about our Collaborators >

Back to Top
 

This links to an external website.

Continue